Induction Failure in de novo Acute Myelogenous Leukemia is Associated with Expression of High Levels o CD34 Antigen by the Leukemic Blasts

Leukemia and Lymphoma

Volumn 26, Issue 42067, 1997, Pages 299-306

  Dalal, Bakul I ^a   wu, Vivian ^a   Barnettc, Michael J ^a   Horsman, Douglas E ^b   Spinelli, John I ^a   Naiman, Sheldon C ^a   Shepherd, John D ^a   Nantel, Stephen H ^a   Reece, Donna E ^a   Sutherland, Heather J ^a   Klingemann, H G ^a   Phillips, Gordon L ^a  

^a Vancouver Hapital Health Sciences Center   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Acute myelogenous leukemia; AML; CD34; prognosis; remission

Indexed keywords

CD33 ANTIGEN; CD34 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLAST CELL; FLUORESCENCE; HUMAN; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DAUNORUBICIN; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION;

EID: 9844253896     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428199709051779     Document Type: Article

References (39)

1. Schmitt C., Eaves C.J., Lansdorp P.M. Expression of CD34 on human B cell precursors. Clinical and Experimental Immunology 1991; 85: 168 – 173
2. Loken M.R., Shah V.O., Dattilio K.L., Civin C.I. Flow cytornetric analysis of human bone marrow 11. Normal B lymphocyte development. Blood 1987; 70: 1316 – 1324
3. Lansdorp P.M., Sutherland H.J., Eaves C.J. Selective expression of CD45 isoforms on functional subpopulations of CD34+ hematopoietic cells from human bone marrow. Journal of Experimental Medicine 1990; 172: 363 – 366
4. Lansdorp P.M., Dougherty G.J., Humphries R.K. CD34 epitopes. Leukocyte typing IV, white cell differentiation antigens, W. Knapp, B. Dörken, W.R. Gilkes, E.P. Reiber, R.E. Schmidt, H. Stein, A. E. G. Kr. von dem Borne. Oxford Univ Press, Oxford England 1989; 826
5. Andrews R.G., Singer J.W., Bernstcin I.D. Monoclonal antibody 12.8 recognizes a 115 kD molecule present on both unipotent and multipotent hematopoietic colony-forming cells and their precursors. Blood 1986; 67: 842 – 845
6. Civin C.I., Strauss L.C., Brovall C., Facker J.F., Schwartz J.F., Shaper J.H. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-la cells. Journal of Immunology 1984; 133: 157 – 165
7. Beschorner W.E., Civin C.I., Strauss L.C. Localization of hematopoietic progenitor cells in tissue with the anti-My-10 monoclonal antibody. American Journal of Pathology 1985; 119: 1 – 4
8. Terstappen L. W. M. M., Huang S., Safford M., Lansdorp P.M., Loken P.M. Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells. Blood 1991; 77: 1218 – 1227
9. Bemstein I.D., Andrews R.G., Zsebo K.M. Recombinant human stem cell factor enhances the formation of colonies by the CD34+lin- cells and the generation of colony-forming cell progeny from CD34+lin- cells cultured with interleukin-3, granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor. Blood 1991; 77: 2316 – 2321
10. Dehili N., Issaad C., Masse J.-M., Guichard J., Katz A., Breton-Gorius J., Vainchenker W. Expression of CD34 and platelet glycoprotein during human megakaryocytic differentiation. Blood 1992; 80: 3022 – 3035
11. Geller R.B., Zahurak M., Hurwitz C.A., Burke P.J., Karp J.E., Piantadosi S., Civin C.I. Prognostic importance of immunophenotyping in adults with acute myelocytic leukemia: the significance of the stem-cell glycoprotein CD34 (MY10). British Journal of Haematology 1990; 76: 340 – 347
12. Terstappen L.W., Safford M., Unterhalt M., Konemann S., Zurlutter K., Piechotka K., Drescher M., Aul C., Buchner T., Hiddemann W. Flowcytometric characterization of acute myeloid leukemia: IV. Comparison to the differentiation pathway of normal hematopoietic progenitor cells. Leukemia 1992; 6: 993 – 1000
13. Campos L., Guyotat D., Archimbaud E., Calmard-Oriol P., Tsuruo T., Troncy J., Treille D., Fiere D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia at diagnosis. Blood 1992; 79: 473 – 476
14. Guinot M., Sanz G.F., Sempere A., Arilla M.J., Jarque I., Gomis F., Sanz M.A. Prognostic value of CD34 expression in de novo acute myeloblastic leukemia. British Journal of Haematology 1991; 79: 533 – 534
15. Campos L., Guyotat D., Archimbaud E., Devaux Y., Treille D., Larese A., Maupas J., Gentilhomme O., Ehrsam A., Fiere D. Surface marker expression in adult acute myeloid leukemia: correlations with initial characteristics, morphology and response to therapy. British Jonrnal of Haematology 1989; 72: 161 – 6
16. Borowitz M.J., Gockeman J.P., Moore J.O., Civin C.I., Page S.O., Robertson J., Bigner S.H. Clinicopathologic and cytogenetic features of CD34 (My 10)-positive acute nonlymphocytic leukemia. American Journal of Clinical Pathology 1989; 91: 265 – 70
17. Lee E.J., Yang J., Leavitt R.D., Testa J.R., Civin C.I., Forrest A., Schiffer C.A. The significance of CD34 and TdT determinations in patients with untreated de novo acute myeloid leukemia. Leukemia 1992; 6: 1203 – 1209
18. Solary E., Casasnovas R.O., Campos L., Bene M.C., Faure G., Maingon P., Falkenrodt A., Lenormand B., Genetet N. Surface markers in adult acute myeloblastic leukemia: correlation of CD19+, CD34+ and CD 14+/DR—phenotypes with shorter survival. Groupe d'Etude Immunologique des Leucemies (GEIL). Leukemia 1992; 6: 393 – 399
19. Te Boekhorst P. A. W., de Leeuw K., Schoester M., Wittebol S., Nooter K., Hagemeijer A., Lowenherg B., Sonneveld P. Predominance of functional multidrug resistance (MDRI) phenotype in CD34+ acute myeloid leukemia cells. Blood 1993; 82: 3157 – 3162
20. Selleri C., Notaro R., Catalano L., Fontana R., del Vecchio L., Rotoli B. Prognostic irrelevance of CD34 in acute myeloid leukemia. British Journal of Haematology 1992; 82: 479 – 482
21. Ciolli S., Leoni F., Caporale R. CD34 Expression fails to predict the outcome in adult acute myeloid leukemia. Hematologica 1993; 78: 151 – 155
22. Sperling C., Buchner T., Sauerland C., Fonatsch C., Thiel E., Ludwig W.D. CD34 expression in de novo acute myeloid leukaemia. Br J Haematol 1993; 85: 635 – 637
23. Davey F.R., Nelson D.A. Periodic acid Schiff stain. Hematology2nd ed., W.J. Williams, E. Beutler, A.J. Erslev, R.W. Rundles. McGraw Hill, New York 1977; 1630 – 1632
24. Yam L.T., Li C.Y., Crosby W.H. Cytochemical identification of monocytes and granulocytes. American Journal oj Cliniccil Puthology 1971; 55: 283 – 288
25. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D. A. G., Ciralnick H.R., Sultan C. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). Annals of Internal Medicine 1985a; 108: 460 – 462
26. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D. A. G., Gralnick H.R., Sultan C. Proposed revised criteria for the classification of acute myelogenous leukemia. Annals of Internal Medicine 1985; 103: 626 – 629
27. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D. A. G., Gralnick H.R., Sultan C. Proposal for the recognition of minimally differentiated acute myelogenous leukemia (AML-MO). British Journal of Haematology 1991; 78: 325 – 329
28. ISCN. Guidelines for cancer cytogentics Supplement to an International System for Human Cytogenetic Nomenclarure, F. Mitelman. S. Karger, Basel 1991
29. Cheson B.D., Cassileth P.A., Head D.R., Schiffer C.A., Bennett J.M., Bloornfield C.D., Brunning R., Gale R.P., Grever M.R., Keating M.J., Sawitsky A., Stass S., Weinstein H., Woods W.G. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myelogenous leukemia. Jorunal of Clinical Oncology 1990; 8: 813 – 819
30. Askew D.S., Eaves A.C., Takei F. NHL-30.5: a monoclonal antibody reactive with an acute myeloid leukemia (AML)-associated antigen. Leukemia Research 1985; 9: 135 – 145
31. Shepherd J.D., Reece D.E., Barnett M.J., Klingemann H.G., Nantel S.H., Sutherland H.J., Philips G.L. Induction therapy for acute myelogenous leukemia in patients over 60 years with intermediate-dose cytosine arabinoside, mitoxantrone and etoposide. Leukemia & Lymphoma 1993; 9: 211 – 215
32. Shepherd J.D., Reece D.E., Barnett M.J., Nantel S.H., Klingemann H.-G., Sutherland H.J., Spinelli J.J., Phillips G.L. Induction chemotherapy with continuous infusion ara-c, mitoxantrone, and VP-16 for patients less than 65 years old with acute myeloid leukemia. Proceedings of American Society of Clinical Oncology 1994; 13: 308, 1994
33. Conover W.J. Practical Nonparametric Statistics2nd Ed. John Wiley & Sons, New York 1980; 229 – 239
34. Sutherland D.R., Marsh J.C., Davidson J., Baker M.A., Keating A., Mellors A. Differential sensitivity of CD34 epitopes to cleavage by Pasteurella haemolytica glycoprotease: implications for purification of CD34-positive progenitor cells. Experimenral Hematology 1992; 20: 590 – 599
35. Hanson C.A., Ross C.W., Schnitzer B. Anti-CD34 immunoperoxidase staining in paraffin section of acute leukemia: Comparison with tlow cytometric immunophenotyping. American Journal of Clinical Pathology 1992; 23: 26 – 32
36. Siena S., Bregni M., Brando B., Belli N., Lansdorp P.M., Bonadonna G., Gianni M. Flow cytometry to estimate circulating hematopoietic progenitors for autologous bone marrow transplantation comparative analysis of different CD34 monoclonal antibodies. Haematologica 1991; 76: 330 – 333
37. Smith B.R. Qualitative versus quantitative immunophenotyping. Annals of the New York Academy of Sciences 1993; 677: 152 – 154
38. Udomsakdi C., Eaves C.J., Sutherland H.J., Lansdorp P.M. Separation of functionally distinct subpopulalions of primitive human hematopoietic cells using rhodamine-123. Experimental Haematology 1991; 19: 338 – 342
39. Bernstein I.D., Singer J.W., Smith F.O., Andrews R.G., Flowers D.A., Petersens J., Steinmann L., Najfeld V., Savage D., Fruchtman S., Arlin Z., Fialkow P.J. Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia. Blood 1992; 79: 1811 – 1816